TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update

Rhea-AI Summary

• English
• French
• German
• Italian
• Korean
• Spanish

TG Therapeutics, Inc. (NASDAQ: TGTX) will host a conference call on May 1, 2024, to discuss the first quarter financial results and the business outlook for 2024. The call will be led by Michael S. Weiss, Chairman and CEO. Participants can join via phone or webcast.

Conference call to be held tomorrow, Wednesday, May 1, 2024, at 8:30 AM ET

NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held tomorrow, Wednesday, May 1, 2024, at 8:30 AM ET to discuss results for the first quarter of 2024 and provide a business outlook for 2024. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.

In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics First Quarter Update Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.

TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.

ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI^® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.

CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6

FAQ

When will TG Therapeutics host the conference call?

TG Therapeutics will host the conference call on May 1, 2024.

What will be discussed during the conference call?

The conference call will cover the first quarter financial results and provide a business outlook for 2024.

Who will lead the conference call?

Michael S. Weiss, Chairman and CEO of TG Therapeutics, will lead the conference call.

How can participants join the conference call?

Participants can join the call by dialing 1-877-407-8029 (U.S.) or 1-201-689-8029 (outside the U.S.), with the Conference Title: TG Therapeutics First Quarter Update Call.

Will there be a webcast available for the conference call?

Yes, a live webcast of the presentation will be available on the Events page of TG Therapeutics' website at www.tgtherapeutics.com.